Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao'er Huashi Oral Liquid is a traditional Chinese patent medicine (TCM) formulated as an oral liquid. It is primarily indicated for pediatric patients to treat functional dyspepsia, functional constipation, and other digestive disorders associated with food accumulation transforming into heat. The formulation consists of several traditional Chinese medicinal herbs, including charred hawthorn (shanzha), charred medicated leaven (shenqu), malt (maiya), charred areca seed (binglang), common burreed rhizome (sanling), rhubarb (dahuang), and zedoary rhizome (ezhu). It is manufactured by Xiangxue Pharmaceutical, and its clinical efficacy has been evaluated in Phase 4 trials sponsored by institutions such as the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiao'er Huashi Oral Liquid.